Tirzepatide Linked to 1.5-Point Lower One-Year MACE Risk Versus Sitagliptin in 53,000-Patient Claims Analysis

Researchers analyzed U.S. insurance claims from patients averaging age 70, comparing new users of tirzepatide (n=35,353) against sitagliptin (n=17,618) chosen as a neutral comparator. They tracked a composite of myocardial infarction, ischemic stroke, and all-cause death for up to one year while adjusting for age, sex, race, BMI, prior cardiac events, comorbidities, and concurrent medications. Follow-up ended at treatment discontinuation or plan disenrollment.

Absolute MACE incidence differed by 1.5 percentage points; tirzepatide showed a 33% relative reduction in myocardial infarction with no detectable difference in stroke. Secondary reductions appeared in infection-related hospitalizations (NNT 48) and all-cause mortality (NNT 122). These patterns echo earlier GLP-1 agonist trials yet add real-world data on dual GIP/GLP-1 agonism in an older, higher-risk population.

Residual confounding by indication remains plausible because tirzepatide users may have differed in unmeasured frailty or adherence. The one-year median follow-up also limits insight into longer-term durability or rare safety signals. The ongoing SURPASS-CVOT randomized trial will test whether these associations translate into confirmed event reduction.

If SURPASS-CVOT meets its primary endpoint, guidelines may expand tirzepatide indications to include cardiovascular risk reduction alongside glycemic control, prompting payers to reassess access criteria for patients with both diabetes and atherosclerotic disease.